India News | Biological E Gets WHO Nod to Be Additional Facility for Production of Johnson & Johnson Covid Vaccine
Get latest articles and stories on India at LatestLY. Biological E has received the WHO nod to be an additional facility for production of Johnson & Johnson COVID-19 vaccine.
New Delhi, Jun 22 (PTI) Biological E has received the WHO nod to be an additional facility for production of Johnson & Johnson COVID-19 vaccine.
"Congratulations to @biological_e on its @WHO approval as an additional manufacturing site for the Janssen/Johnson & Johnson COVID-19 vaccine! Great progress for the Quad Vaccine and #USIndiaHealth partnerships through U.S. technical support and @DFCgov financing," the US embassy in India said in a tweet on Wednesday.
India's first indigenously developed RBD protein subunit vaccine, Biological E's Corbevax, is currently being used to inoculate children in the age group of 12 to 14 years.
The Drugs Controller General of India (DCGI) recently approved Corbevax as a precaution dose for those aged 18 and above.
Also Read | Agnipath Scheme: AAP's Sanjay Singh Urges PM Narendra Modi to Rollback the Scheme.
(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)